Gilead Sciences has worked for decades to build a dominant presence in HIV treatment and prevention, but the company is only years into its buildout of an oncology portfolio, with even more work to do to create a comparable pipeline in inflammation. CEO Daniel O’Day and other executives shed some light on the plans to expand in inflammation during the J.P. Morgan Healthcare Conference, just days after buying inflammation assets from LEO Pharma.
Key Takeaways
- Gilead is diversifying its portfolio over the long term, with inflammation as an important but earlier-stage area of growth, through both internal R&D and external business development.
- The company’s recent deal to acquire LEO Pharma’s STAT6 program and the $4.3bn CymaBay buy last year added a preclinical opportunity and a commercial asset in inflammation
On 12 January, Gilead announced it will pay $250m up front for LEO’s preclinical oral small molecule STAT6 inhibitors, which may have potential in atopic dermatitis, asthma and chronic obstructive pulmonary disease (COPD), among other indications. O’Day told reporters during a media briefing on the sidelines of the J.P
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
